Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:
”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.
This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.
Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.
Patients living with HHT can’t wait for effective therapies to improve their lives.”
Quoting Vaderis Therapeutics AG‘s post:
”Moving Forward Together for the HHT Community
We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).
This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.
While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.
As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.
Read the full press release.”
Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis